S
Sergio Bernasconi
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 121
Citations - 7946
Sergio Bernasconi is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Cell adhesion molecule & Monocyte. The author has an hindex of 45, co-authored 113 publications receiving 7703 citations. Previous affiliations of Sergio Bernasconi include University of Brescia & University of Trieste.
Papers
More filters
Journal ArticleDOI
Regulation of the chemokine receptor CXCR4 by hypoxia.
Tiziana Schioppa,Badarch Uranchimeg,Alessandra Saccani,Subhra K. Biswas,Andrea Doni,Annamaria Rapisarda,Sergio Bernasconi,Simona Saccani,Manuela Nebuloni,Luca Vago,Alberto Mantovani,Alberto Mantovani,Giovanni Melillo,Antonio Sica +13 more
TL;DR: It is described that oxygen availability is a determinant parameter in the setting of chemotactic responsiveness to stromal-derived factor 1 (CXCL12), and the Hyp–Hyp-inducible factor 1 α–CXCR4 pathway may regulate trafficking in and out of hypoxic tissue microenvironments.
Journal ArticleDOI
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
Josée Golay,Luisella Zaffaroni,Thomas Vaccari,Thomas Vaccari,Manuela Lazzari,Manuela Lazzari,Gian Maria Borleri,Gian Maria Borleri,Sergio Bernasconi,Sergio Bernasconi,Francesco Tedesco,Francesco Tedesco,Alessandro Rambaldi,Alessandro Rambaldi,Martino Introna,Martino Introna +15 more
TL;DR: It is concluded that CDC and ADCC are major mechanisms of action of rituximab on B-cell lymphomas and that a heterogeneous susceptibility of different lymphoma cells to complement may be at least in part responsible for the heterogeneity of the response of different patients to ritUXimab in vivo.
Journal ArticleDOI
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
Josée Golay,Manuela Lazzari,Valeria Facchinetti,Sergio Bernasconi,Gianmaria Borleri,Tiziano Barbui,Alessandro Rambaldi,Martino Introna +7 more
TL;DR: Data demonstrate that CD20, CD55, and CD59 are important factors determining the in vitro response to rituximab and complement and indicate potential strategies to improve the clinical response to this biologic therapy.
Journal ArticleDOI
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.
Rupert P. M. Negus,Gordon Stamp,Michele G. Relf,Frances Burke,Saleem T. A. Malik,Sergio Bernasconi,Paola Allavena,Silvano Sozzani,Alberto Mantovani,Frances R. Balkwill +9 more
TL;DR: It is concluded that the macrophage chemoattractant MCP-1 is produced by epithelial ovarian cancer and that the tumor cells themselves are probably a major source.
Journal ArticleDOI
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells.
Nives Jonjić,Giuseppe Peri,Sergio Bernasconi,Francesca L. Sciacca,Francesco Colotta,Pier Giuseppe Pelicci,Luisa Lanfrancone,Alberto Mantovani +7 more
TL;DR: Results indicate that mesothelial cells can express a set of adhesion molecules and chemotactic cytokines overlapping with, but distinct from, that expressed in vascular endothelium, and that these are functionally relevant for interacting with mononuclear phagocytes.